AbbVie

News

NHS saving £300m with Humira biosimilar deal

The NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of AbbVie’s Humira inflammatory diseases drug.

News

BMS, AbbVie get FDA OK for new myeloma regimen

Bristol-Myers Squibb and AbbVie have picked up another FDA approval for their multiple myeloma drug Empliciti that they hope will help drive uptake of the drug.

News

AbbVie, Roche eye first-line use of Venclexta in leukaemia

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena.

News

Chronic lymphocytic leukemia (CLL) is a type of cancer of the blood and bone marrow - the spongy tissue inside bones where blood cells are made.

AbbVie's CLL drug Venclyxto too expensive for NHS, says NICE

NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche's MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for

News

Samsung Bioepis' Humira biosimilar launches in EU

Samsung Bioepis has become the latest biosimilars company to confirm it has launched a cheaper near-copy of AbbVie’s Humira inflammatory diseases blockbuster, after its European patent expi

News

Billions up for grabs as EU patent on AbbVie's Humira expire...

The patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a host of cheaper biosimilars to hit the market.

NHS saving £300m with Humira biosimilar deal

BMS, AbbVie get FDA OK for new myeloma regimen

AbbVie, Roche eye first-line use of Venclexta in leukaemia

AbbVie's CLL drug Venclyxto too expensive for NHS, says NICE

Samsung Bioepis' Humira biosimilar launches in EU

Billions up for grabs as EU patent on AbbVie's Humira expire...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

AbbVie

Editor's Picks